PharmaBiome AG
Functional microbiome therapies.
PharmaBiome develops a pipeline for the use of beneficial gut bacteria as an innovative, standardized and safe therapeutic product to treat diseases caused by functional deficiencies in the microbiome (i.e. gut flora), with an initial focus on ulcerative colitis (UC). Using its proprietary technology platform including isolation, cultivation and rational assembly of intestinal bacterial mixtures, PharmaBiome develops tailored microbiome products. The flexibility and speed of development are a unique advantage to penetrate the multibillion markets of untreatable intestinal diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
27.03.2023
New chapter in a long-standing, successful partnership for PharmaBiome (startupticker.ch)
08.07.2020
PharmaBiome secures CHF 1.75 million bridge funding (startupticker.ch)
08.07.2020
PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members (venturelab.swiss)
05.03.2020
Die Finalisten des ZKB Pionierpreis Technopark stehen fest (startupticker.ch)
21.01.2020
BaseLaunch accelerator nominates 4 startups for phase 2 (startupticker.ch)
Last Tweets
22.06.2023
No Jobs
Videos
Spark Award 2018
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Spark Award
ETH transfer has been excited to celebrate the most promising invention of the year for the first time based on a thorough evaluation of the originality, patent strength and commercial potential. Each year the winner(s) will be rewarded with the “Spark Award” as a symbol of the inventive spirit and the innovative strength of ETH-Zurich’s scientists.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
PharmaBiome AG
Functional microbiome therapies.
Website:
www.pharmabiome.com/
Headquarter:
Zürich
Foundation Date:
February 2015
Technology:
- Biotech
Sectors:
- Biotech
Support received
